Skip to content

13F-HR filed by BB BIOTECH AG

BB BIOTECH AG filed this 13F-HR for the quarter ended 2016-12-31, filed 2017-02-14, with 29 holding rows worth $2,700,053,000.

Accession
0000950123-17-002291
Filed
2017-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2016

A holdings report, 29 entries on the cover page, a total value of $2,700,053,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,700,058,000 with VALUE read as thousands by filing date, 13F file number 028-06964. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerBiotech Focus N V 028-11193
  • included managerBiotech Invest N V 028-11191
  • included managerBiotech Target N V 028-11189
  • included managerBiotech Growth N V 028-11194

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CELGENE CORP151020104COM3,459,298$400,414,000thousands by filing date
INCYTE CORP COM45337C102Stock3,879,822$389,030,000thousands by filing date
IONIS PHARMACEUTICALS INC COM462222100Stock6,913,172$330,657,000thousands by filing date
Gilead Sciences,Inc.375558103COM2,774,596$198,689,000thousands by filing date
RADIUS HEALTH INC750469207COM NEW4,360,399$165,826,000thousands by filing date
ALEXION PHARMACEUTICALS INC015351109COM1,229,428$150,421,000thousands by filing date
TESARO INC881569107COM974,582$131,062,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM3,151,552$121,965,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM2,809,528$117,242,000thousands by filing date
Vertex Pharmaceuticals Incorporated92532F100COM1,415,445$104,276,000thousands by filing date
REGENERON PHARMACEUTICALS COM75886F107Stock245,000$89,937,000thousands by filing date
HALOZYME THERAPEUTICS INC COM40637H109Stock7,599,832$75,086,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM1,022,439$52,206,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock1,191,338$44,604,000thousands by filing date
MYOVANT SCIENCES LTDG637AM102COMMON STOCK-FO3,192,835$39,719,000thousands by filing date
MACROGENICS INC556099109COM1,920,000$39,245,000thousands by filing date
KITE PHARMA INC49803L109COM800,000$35,872,000thousands by filing date
JUNO THERAPEUTICS INC48205A109COM1,870,000$35,250,000thousands by filing date
ALDER BIOPHARMACEUTICALS INC014339105COM1,685,150$35,051,000thousands by filing date
INTERCEPT PHARMACEUTICALS IN45845P108COM255,719$27,784,000thousands by filing date
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK1,575,000$23,767,000thousands by filing date
PROTHENA CORP PLC SHSG72800108Stock350,000$17,217,000thousands by filing date
AVEXIS INC05366U100COM352,800$16,839,000thousands by filing date
ESPERION THERAPEUTICS INC NEW COM29664W105Stock1,308,542$16,383,000thousands by filing date
CIDARA THERAPEUTICS INC COM NEW171757107Stock1,043,824$10,856,000thousands by filing date
NOVAVAX INC670002104COMMON STOCK8,330,000$10,496,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM682,912$7,451,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK241,991$7,429,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM1,279,340$5,284,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-17-002291this filing2017-02-14acceptance time not in the bulk data set